Symphogen
Lyngby · Founded 2000
About Symphogen
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
Company Facts
- Founded: 2000
- Legal name: Symphogen A/S
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $375.2M
- Funding stage: M&A
- Last round: Debt Financing (Oct 2015)
- Website: symphogen.com
- Phone: 45 45 26 50 50
Social Profiles
Canonical: https://fsome.com/organization/symphogen-8372530 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.